The Lancet Commission on prostate cancer: planning for the surge in cases

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal…

• UD
  U.S. Department of Defense
• PC
  Prostate Cancer Foundation
• A
  Amgen
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• GS
  Gilead Sciences
• AN
  Australian Nuclear Science and Technology Organisation
• MF
  Movember Foundation
• E
  Exelixis
• NI
  National Institute for Health and Care Research
• IO
  Institute of Cancer Research
• PC
  Prostate Cancer UK
• AP
  Astellas Pharma
• I
  Ipsen
• PM
  Peter MacCallum Foundation
• MR
  Medical Research Council

  Awards: MC_UU_00004/01, MC_UU_00004/08, MC_UU_00004/02
• NH
  National Health and Medical Research Council
• NC
  National Cancer Institute